NCT02111850 2022-03-29
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
National Institutes of Health Clinical Center (CC)
Mie University
National Institutes of Health Clinical Center (CC)
Mie University